Answers are in our DNA™
Joined January 2010
- Tweets 4,432
- Following 353
- Followers 2,237
- Likes 1,878
2,794 Photos and videos
Jun 12
Our digital #pathology library is rich with real clinical context—built to support your AI models and fuel discovery. Let’s talk image-powered research: neogenomics.com/oncology-dat….
#DigitalPathology #AIinOncology #NeoGenomics
2
1
35
Jun 11
When cancer leaves only a trace… can you still detect it? Join us for a #webinar with Basem Goueli, MD, PhD, MBA, as he explores how RaDaR® ST is advancing MRD detection down to 1 part per million (ppm): engagez.net/neowebinar16#9pn….
1
42
Jun 9
During #CancerSurvivor Month, we’re recognizing the importance of tools informed by science. RaDaR® ST is supported by an expanding base of clinical evidence, contributing to continued learning in cancer care and survivorship. Learn more: neogenomics.com/providers/on…
2
56
Jun 8
Register for Liquid Biopsy: Advancing Precision Care in Oncology 🔗 engagez.net/neowebinar15. This #webinar will explore how a minimally invasive approach can complement tissue testing & improve patient outcomes through faster, more personalized treatment decisions.
1
44
Jun 5
The NEO AML Express assay offers class-leading turnaround times, a single report that provides a comprehensive NGS-based assessment, and rapid diagnostic, prognostic, and therapeutic information to inform personalized treatment decisions: neogenomics.com/providers/te….
2
2
62
Jun 3
RaDaR® ST offers a streamlined workflow for actionable insights, helping pharma partners monitor therapeutic response with precision.
See how it works: neogenomics.com/partners/bio…
1
59
Jun 2
#ASCO26 just wrapped up! We had the chance to connect with so many people & discuss how we can work together to advance personalized cancer care across the care continuum. If we didn’t get to meet, or you’d like to continue the discussion, let's connect: mailchi.mp/neogenomics/asco2….
58
Jun 1
The PD-L1 22c3 FDA for Ovarian Carcinoma (neogenomics.com/providers/te…) seamlessly integrates into your existing molecular diagnostic workflow to provide comprehensive patient profiling through our PanTracer™ Portfolio and NeoTYPE® Ovarian assays.
1
31
May 30
It’s Day 1 at the 2026 ASCO® Annual Meeting! Walk over to our booth at #32130, or plan ahead by booking a meeting here: mailchi.mp/neogenomics/asco2….
1
1
59
May 29
During #ASCO26, step into an interactive journey through the cancer care continuum and see how comprehensive clinical solutions, therapeutic development support, and data-driven insights are shaping more informed, individualized decisions at every stage.
49
May 28
We’re showcasing our latest research at the 2026 ASCO® Annual Meeting on June 1st from 9 AM – 12 PM.
Contact us to discuss our findings and their implications for clinical care: mailchi.mp/neogenomics/asco2….
1
1
75
May 27
Whether you’ve just started hearing the term or just had to Google it, we’re here to bring clinicogenomic insights to life. Come see us at #ASCO26, booth #32130, to explore how #clinicogenomic data is advancing precision oncology.
1
53
May 25
On Memorial Day, we remember & honor those who made the ultimate sacrifice for our country. While touring historic #SanDiego veteran sites, including the USS Midway and Rosecrans National Cemetery, we paused in quiet reflection. We invite you to join us in this moment of silence.
98
May 15
NeoGenomics’ c‑MET CDx for NSCLC IHC assay is part of our comprehensive #LungCancer testing portfolio—advancing precision oncology through biomarker‑driven care: neogenomics.com/providers/te…
#NSCLC #OncologyDiagnostics
3
167
May 13
We’re gearing up for #ASCO26! Request a meeting with us here: mailchi.mp/neogenomics/asco2… to see how we’re advancing personalized cancer care across the care continuum.
See all that #NeoGenomics is sharing this year, from poster presentations to an interactive video experience.
1
119
May 12
To obtain confidence in every result, and simplify complex myeloid cases, #NeoGenomics provides clarity: neogenomics.com/providers/on…
Neo Comprehensive – Myeloid Disorders uses DNA and RNA NGS to uncover actionable insights for MDS and CMML.
#MDS #CMML #Myeloid #HematologicalCancer
2
102
May 11
We’re always innovating, because your patients deserve the chance to uncover targeted therapy options. Visit us online to learn about how we’ve expanded our companion diagnostic portfolio with The PD-L1 22C3 FDA for Ovarian Carcinoma assay: neogenomics.com/providers/te….
1
3
107
May 10
Happy Mother’s Day! Today, we're celebrating each & every one of the amazing women who inspire us with their boundless love, patience, dedication, & wisdom. We are so proud to support mothers at NeoGenomics, from lactation rooms to gifts—like this one that we send to new mothers.
2
67
May 8
PanTracer Pro combines broad genomic profiling with tumor-specific testing, including IHC and HRD scoring, to deliver therapy-guiding insights in one order: neogenomics.com/providers/on…
1
2
101
May 7
Make confident, data-driven genomic decisions even when tumor tissue is limited or unavailable with TSO 500 ctDNA v2. Contact us to learn more: neogenomics.com/tso500
2
2
89